Infections are a common cause of morbidity and mortality in patients with lymphoid cancer. Because cancer therapeutics, including new targeted therapies and immunotherapies, are evolving, clinicians need to be aware of additional risk factors and infections that may arise in patients treated with these agents. This article highlights fundamental issues in treating patients with lymphoid cancer, including risk factors for infection, screening for infectious diseases, and recommendations for antimicrobial prophylaxis in patients with lymphoid cancers. We present 4 scenarios of patients with lymphoid cancers who have various infections, and we describe a treatment approach based on a combination of evidence-based data and experience because objective data are limited regarding infections, especially with newer agents. The goal of this discussion is to provide a framework for institutions and health care providers to help them develop their own approach to preventing and treating infections in patients with lymphoid cancer.

中文翻译：

---

我如何管理淋巴癌患者的感染风险和预防。

感染是淋巴癌患者发病和死亡的常见原因。由于癌症疗法（包括新的靶向疗法和免疫疗法）正在不断发展，临床医生需要了解使用这些药物治疗的患者可能出现的其他风险因素和感染。本文重点介绍了治疗淋巴癌患者的基本问题，包括感染的危险因素、传染病的筛查以及对淋巴癌患者进行抗菌预防的建议。我们提出了 4 种患有各种感染的淋巴癌患者的情况，并且我们描述了一种基于循证数据和经验相结合的治疗方法，因为关于感染的客观数据有限，尤其是使用新药物时。